Literature DB >> 11768607

Micro-metastases in axillary lymph nodes: an increasing classification and treatment dilemma in breast cancer due to the introduction of the sentinel lymph node procedure.

V C Tjan-Heijnen1, P Buit, L M de Widt-Evert, T J Ruers, L V Beex.   

Abstract

BACKGROUND: Sentinel lymph node (SN) biopsy will increasingly replace axillary lymph node dissection (ALND) for staging in breast cancer. For daily practice, examination of the SN by serial sectioning (SS) and/or immunohistochemistry (IHC) is being promoted. Use of these techniques may result into stage migration due to the increased detection of micro-metastases. The consequence may be overshooting of patients with adjuvant therapy, as the prognostic relevance of (small) micro-metastases and isolated tumor cells is unclear.
METHODS: The prognostic impact of micro-metastases is determined by reviewing ALND studies with a follow up of at least 5 years, including more than 100 patients, before the SN era. Furthermore, studies in which conventionally haematoxylin-eosin (H&E) negative SNs are investigated for occult metastases by SS and/or IHC are reviewed.
RESULTS: In only one of eight studies, occult metastases were an independent risk factor for reduced survival. The outcome is dependent on the size of the nodal metastasis. IHC and SS as used in the SN procedure indeed induce a shift from pNO to pN1a (according to TNM).
CONCLUSION: By the thorough pathologic examination of the SN, isolated tumor cells and micro-metastases are more frequently detected. We propose to classify small micro-metastases (<0.5 mm) in a separate pN1a(min) category (min for minimal) to prevent stage migration. As the prognostic relevance of isolated tumor cells and (small) micrometastases has not been proven, the value of adjuvant therapy can be questioned for patients with otherwise good prognostic factors.

Entities:  

Mesh:

Year:  2001        PMID: 11768607     DOI: 10.1023/a:1012938825396

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  7 in total

1.  Adjuvant chemotherapy for breast cancer patients with axillary lymph node micrometastases.

Authors:  Holm Eggemann; Atanas Ignatov; Madeleine Hetterich; Michael Gerken; Olaf Ortmann; Elisabeth C Inwald; Monika Klinkhammer-Schalke
Journal:  Breast Cancer Res Treat       Date:  2021-03-15       Impact factor: 4.872

Review 2.  Breast cancer and sentinel lymph node micrometastases: indications for lymphadenectomy and literature review.

Authors:  G Zanghì; G Di Stefano; A Caponnetto; R Vecchio; A Lanaia; A La Terra; V Leanza; F Basile
Journal:  G Chir       Date:  2014 Nov-Dec

3.  Supervised automated microscopy increases sensitivity and efficiency of detection of sentinel node micrometastases in patients with breast cancer.

Authors:  W E Mesker; H Torrenga; W C R Sloos; H Vrolijk; R A E M Tollenaar; P C de Bruin; P J van Diest; H J Tanke
Journal:  J Clin Pathol       Date:  2004-09       Impact factor: 3.411

4.  Prognostic value of lymph node micrometastases in breast cancer: a multicenter cohort study.

Authors:  Paul D Gobardhan; Sjoerd G Elias; Eva V E Madsen; Bob van Wely; Frits van den Wildenberg; Evert B M Theunissen; Miranda F Ernst; Marike C Kokke; Carmen van der Pol; Inne H M Borel Rinkes; Jan H Wijsman; Vivian Bongers; Joost van Gorp; Thijs van Dalen
Journal:  Ann Surg Oncol       Date:  2010-12-14       Impact factor: 5.344

5.  The value of immunohistochemistry in sentinel lymph node histopathology in breast cancer.

Authors:  M B Klevesath; L G Bobrow; S E Pinder; A D Purushotham
Journal:  Br J Cancer       Date:  2005-06-20       Impact factor: 7.640

6.  Impact of Post-Mastectomy Radiation Therapy for Sentinel Lymph Node Micrometastases in Early-Stage Breast Cancer Patients.

Authors:  Hua Luo; Ou Ou Yang; Jun Ling He; Tian Lan
Journal:  Med Sci Monit       Date:  2022-01-30

7.  Detection of metastases in sentinel lymph nodes of breast cancer patients by multiple mRNA markers.

Authors:  B Weigelt; P Verduijn; A J Bosma; E J Rutgers; H L Peterse; L J van't Veer
Journal:  Br J Cancer       Date:  2004-04-19       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.